Personalised medicine company Curidium Medica says that it is stepping up its marketing this year.
There was no turnover in 2007 because Curidium is still developing its technology and looking for partners. Curidium lost £1.17m after spending £390,000 on research and development.
At the end of 2007 Curidium signed a partnership with Takeda Research Investment, which will use Curidium’s Homomatrix technology to identify a treatment for a depressive disorder. This included a £1.25m investment by Takeda in order to finance research.
Finding more partners is important for Curidium. There was cash of £4.1m in the balance sheet at the end of 2007. That cash will last into next year but new deals will help to drive the share price. However, it is impossible to predict when they will happen.
At 50p, the company is valued at £9.47m. The shares underwent a consolidation of 30 shares into one new share earlier this year. The shares have effectively halved over the past three months.
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.